VDPHL01 oral – Veradermics says its late-stage trial of VDPHL01—a once- and twice-daily, extended-release, orally administered minoxidil formulation—met key efficacy and safety goals, with 79% of once-daily patients and 86% of twice-daily patients reporting improved hair cov
For years, hair loss has been the kind of problem the pharmaceutical industry knew how to treat only imperfectly—topically, inconveniently, and often with lingering tradeoffs. Now, Veradermics is betting that an oral option can finally change the equation.
The biopharmaceutical company announced success in a late-stage clinical trial for VDPHL01, an orally administered, extended-release minoxidil formulation designed for pattern hair loss. In the company’s update, the study met key points and “high goals” for efficacy and safety.
Veradermics said 79% of once-daily patients and 86% of twice-daily patients reported improvement in hair coverage.
“Dermatology has been treating hair loss with a drug borrowed from cardiology. in a formulation never intended for our patients. at doses we arrived at informally. ” said Michael Gold. the study trial investigator. “VDPHL01 is the first oral minoxidil formulation developed specifically for pattern hair loss. and now the first to generate positive Phase 3 results of efficacy and safety.”.
The company also described the growth timeline in the double-blind, placebo-controlled trial: hair growth was detectable by month two, and by month six patients saw total improvement of between 30 and 33 hairs per square centimeter.
The trial recruited roughly 500 men with mild to moderate hair loss, and it was conducted as a double-blind, placebo-controlled study.
Whether this becomes a turning point for patients—and for investors watching a category long dominated by topical and off-label approaches—may hinge on how the benefits compare with the risks that have come with oral minoxidil before.
Minoxidil is already a well-known treatment for hair loss, and Veradermics’ drug is an extended-release version. The company emphasized that minoxidil can be found over the counter to treat hair loss. and that major brands including Hims and Rogaine. as well as Pfizer. have been prominent players in male pattern baldness treatments.
But many oral minoxidil tablets carry warnings about cardiovascular issues, and oral tablets can cause side effects such as lightheadedness, palpitations, swelling, nausea, and vomiting.
Veradermics said that if VDPHL01 is approved, it would be the first FDA-approved non-hormonal oral treatment in the U.S., particularly one without cardiovascular side effects.
Reid Waldman, chief executive officer of Veradermics, framed the trial results as a milestone not just for the company, but for the broader hair-loss treatment landscape.
“These Phase 2/3 clinical study results support our belief that Veradermics’ novel formulation in VDPHL01 can optimize oral minoxidil for significant hair growth while minimizing side effects and cardiac risk. ” Waldman said. “We are optimistic that these results represent a defining milestone for the hair loss community. our company. and investors as we advance this foundational. non-hormonal treatment approach to the clinic for the millions of people with pattern hair loss.”.
The next question is what regulators will make of the balance Veradermics is claiming—higher improvements in hair coverage. paired with an approach intended to reduce the cardiovascular risks associated with other oral minoxidil options. If those claims hold through the approval process. VDPHL01 could push hair-loss care further into mainstream pharmaceuticals. rather than leaving millions relying on topical solutions or managing oral risk profiles.
This reporting reflects Veradermics’ announced results for VDPHL01 and how the company says the study performed. The company’s update did not provide additional trial details beyond the efficacy and safety milestones it highlighted. including the reported hair-coverage improvements and the hair-growth measurements described through month six.
Veradermics VDPHL01 oral minoxidil extended-release minoxidil hair loss pattern baldness Phase 3 trial FDA approval biopharmaceuticals Michael Gold Reid Waldman